| abstract |
It refers to a pharmaceutical formulation in solid oral dosage form comprising: (a) an LSD1 inhibitor which is the di-tosylate salt of Compound 1 or a solvate or hydrate thereof; and (b) an organic acid, where the organic acid can be fumaric acid, citric acid, among others; where the diluent can be lactose monohydrate; where the lubricant can be sodium stearyl fumarate; where the glidant can be colloidal silica, among others. One of the preferred LSD1 inhibitors is the acid di-tosylate salt 1 - {[4- (methoxymethyl) -4 - ({[1R, 2S) -2-phenylcyclopropyl] amino} methyl) piperidin-1-yl] methyl} cyclobutanecarboxylic (di-tosylate salt of compound 1). Said composition modulates the overexpression of lysine-specific demethylase 1 (LSD1). It also refers to a method of treatment against cancer of the lung, liver, skin, among others. |